Meeting
2023 ASCO Annual Meeting
UGT1A1 *28/*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy.
Authors
Megan Wong
City of Hope Comprehensive Cancer Center, Duarte, CA
Megan Wong , Carolyn E. Behrendt , Wai (Kim) Yu , Linda D. Bosserman , Sayeh Moazami Lavasani , Niki Patel , Mina S. Sedrak , Daphne B. Stewart , James Ross Waisman , Yuan Yuan , Joanne E. Mortimer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1033)
DOI
10.1200/JCO.2023.41.16_suppl.1033
Abstract #
1033
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Real world study of racial disparities associated with toxicities of sacituzumab govitecan.
First Author: Shista Priyadarshini
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
First Author: Ayca Gucalp
Poster
2014 ASCO Annual Meeting
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
First Author: Teng Zhu
Poster
2024 ASCO Breakthrough
Characterization of estrogen receptor mutant breast cancer in 3D cell culture.
First Author: Olivia Mayer